Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
White House National Economic Council Director Hassett questions the necessity of Fed rate hikes and criticizes some officials for advocating further tightening policies.
A senior economic official from the White House publicly questioned the necessity of the recent interest rate hikes by the Federal Reserve on Wednesday.
The wave of US Treasury sell-off continues! The largest long-term US Treasury ETF falls to its lowest level in over 20 years, dropping by half from its 2020 peak.
The U.S. long-term Treasury bond market continues to face pressure, with the largest exchange-traded fund tracking long-term U.S. Treasuries closing at its lowest level in over 20 years on Wednesday.
BUZZ-MGM Resorts shares fall after People Inc. withdraws acquisition offer
Crypto prices
More
